Core Viewpoint - The 10th China Pharmaceutical Innovation and Investment Conference highlighted the significant role of capital markets in supporting the globalization of Chinese innovative pharmaceutical companies, with Hong Kong Stock Exchange (HKEX) emerging as a leading platform for biotech financing in 2023 [1] Group 1: Market Performance - HKEX has positioned itself as a vital international financing platform for Chinese biotech companies, with the healthcare sector's IPO financing in Hong Kong ranking first globally this year [1] - As of now, Hong Kong has completed 12 biotech IPOs, raising a total of $1.3 billion, which is the highest globally [1] - The total amount raised through refinancing in the biotech sector has reached $4.1 billion this year, indicating a recovery in market confidence [1] Group 2: Regulatory Environment - The recent strong performance of Hong Kong's healthcare financing market is attributed to three interlinked factors: continuous optimization of regulatory systems, the listing of high-quality innovative companies, and active participation from investors [1] - The market is expected to see a significant rebound by 2025, reaffirming Hong Kong as the preferred listing destination for biotech companies [1]

Group 1 - In 2023, 25.5% of the 55 new listings in Hong Kong are from the healthcare sector, with 14 companies in this industry [1] - The head of Asia Pacific Healthcare Investment Banking at Citigroup noted a significant shift in biotech financing preferences, with companies now favoring the US and Asia Pacific markets over Europe [3] - The trend of companies moving their listings from Europe to the US is increasing, with major pharmaceutical firms considering this shift [3] Group 2 - Hong Kong's biotech ETF has risen by 30% this year, while the US market has shown no performance, indicating a strong local market [4] - The Hang Seng Index has performed well, particularly in the healthcare sector, with biotech stocks increasing by 80% and pharmaceutical companies by 60% [4] - International funds are participating in Hong Kong's biotech sector, as evidenced by recent fundraising activities, indicating a broader interest beyond just mainland Chinese capital [4]